US Pharma MarketingCMS proposes 340B cuts
CMS proposes cutting Medicare 340B drug reimbursements to average sales price minus 33.4%, saving $4.55B in 2027. Hospital groups oppose; legal challenges expected. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
A proposed rule would cut the rates by which Medicare pays hospitals for 340B drugs by more than a third, reviving a similar policy introduced by the first Trump administration.
CMS said on Thursday that ...
Source: Endpoints News